NUNZIA PHARMACEUTICAL Co (NUNZ) financial statements (2022 and earlier)
Company profile
| Business Address |
1627 WEST 14TH STREET LONG BEACH, CA 90813 |
| State of Incorp. | UT |
| Fiscal Year End | December 31 |
| SIC | 8741 - Management Services (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | |||
|---|---|---|---|---|---|---|
| ASSETS | ||||||
| Current Assets | ||||||
| Cash, cash equivalents, and short-term investments | 0 | 2 | 17 | |||
| Cash and cash equivalents | 0 | 2 | 17 | |||
| Prepaid expense | 4 | 3 | ||||
| Total current assets: | 4 | 4 | 17 | |||
| Noncurrent Assets | ||||||
| Other undisclosed noncurrent assets | 5 | 5 | ||||
| Total noncurrent assets: | 5 | 5 | ||||
| TOTAL ASSETS: | 9 | 9 | 17 | |||
| LIABILITIES AND EQUITY | ||||||
| Liabilities | ||||||
| Current Liabilities | ||||||
| Accounts payable and accrued liabilities, including: | 24 | 26 | ||||
| Other undisclosed accounts payable and accrued liabilities | 24 | 26 | ||||
| Due to related parties | 86 | 37 | 44 | 11 | ||
| Other undisclosed current liabilities | 11 | 26 | ||||
| Total current liabilities: | 98 | 63 | 69 | 36 | ||
| Noncurrent Liabilities | ||||||
| Other undisclosed noncurrent liabilities | 23 | 23 | 23 | |||
| Total noncurrent liabilities: | 23 | 23 | 23 | |||
| Total liabilities: | 121 | 86 | 92 | 36 | ||
| Stockholders' equity | ||||||
| Stockholders' equity attributable to parent, including: | (111) | (77) | (75) | (36) | ||
| Additional paid in capital | 101,003 | 92,006 | 92,006 | 29 | ||
| Accumulated deficit | (101,407) | (101,373) | (101,366) | (9,350) | ||
| Other undisclosed stockholders' equity attributable to parent | 293 | 9,290 | 9,285 | 9,285 | ||
| Total stockholders' equity: | (111) | (77) | (75) | (36) | ||
| TOTAL LIABILITIES AND EQUITY: | 9 | 9 | 17 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|
| Operating expenses | (35) | (7) | (16) | (1) | |
| Operating loss: | (35) | (7) | (16) | (1) | |
| Other undisclosed loss from continuing operations before equity method investments, income taxes | (9,000) | ||||
| Net loss available to common stockholders, diluted: | (35) | (7) | (16) | (9,001) | |
Comprehensive Income ($ in thousands)
| 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | ||
|---|---|---|---|---|---|
| Net loss: | (35) | (7) | (16) | (9,001) | |
| Comprehensive loss, net of tax, attributable to parent: | (35) | (7) | (16) | (9,001) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.